China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2025)
China SXT Pharmaceuticals has reported Total Current Liabilities over the past 8 years, most recently at $6.0 million for Q3 2025.
- For Q3 2025, Total Current Liabilities fell 61.94% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, down 61.94%, while the annual FY2025 figure was $6.0 million, 32.46% down from the prior year.
- Total Current Liabilities for Q3 2025 was $6.0 million at China SXT Pharmaceuticals, down from $6.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $18.6 million in Q1 2021 and troughed at $6.0 million in Q3 2025.
- A 5-year average of $11.2 million and a median of $9.1 million in 2023 define the central range for Total Current Liabilities.
- Biggest five-year swings in Total Current Liabilities: skyrocketed 70.26% in 2024 and later plummeted 61.94% in 2025.
- Year by year, Total Current Liabilities stood at $8.9 million in 2021, then dropped by 17.87% to $7.3 million in 2022, then increased by 26.17% to $9.2 million in 2023, then skyrocketed by 70.26% to $15.7 million in 2024, then plummeted by 61.94% to $6.0 million in 2025.
- Business Quant data shows Total Current Liabilities for SXTC at $6.0 million in Q3 2025, $6.0 million in Q1 2025, and $15.7 million in Q3 2024.